Tamtam Try Tamtam free
DuPont logo

DuPont account plan

Innovating essential world innovations

At a glance

DuPont makes healthcare, water, construction and industrial materials: $6,849 million 2025 continuing net sales, about 15,000 employees.

DuPont de Nemours, Inc. (NYSE: DD), headquartered in Wilmington, Delaware, sells engineered materials and solutions to manufacturers and distributors in healthcare, water, construction and industrial markets, under brands such as Tyvek, Tychem, FilmTec, Amberlite, Styrofoam, Corian, Vespel and Molykote. It has subsidiaries in about 50 countries, manufacturing in about 20, and approximately 15,000 employees at December 31, 2025. Continuing net sales were $6,849 million in 2025 (+2%), with income from continuing operations of $98 million and a net loss of $738 million after an $836 million loss from discontinued operations. 2025 was the first year of the "New DuPont": the electronics business was spun off as Qnity Electronics on November 1, 2025, and the Aramids business was sold to Arclin (TJC) on April 1, 2026.

Business units

Strategic priorities

Above-market organic growth
The 2026 priorities set at the September 2025 Investor Day are to "drive above-market organic growth, continue to build out a robust business system, deploy a balanced capital allocation model". 2026 guidance was raised to organic growth of approximately 4.5% and sales of about $7.19 billion.
Healthcare and water growth
Growth is expected in medical packaging and medical devices, and in reverse osmosis and ion exchange for industrial and municipal water. The early 2027 view is mid-single-digit growth in healthcare and water excluding the Middle East.
Business system and productivity
DuPont targets net productivity of 3% of COGS (a little over 2% in Q3 2026) and on-time-in-full of 95%, now in the low 80s. 80/20 was piloted on about $700 million of Diversified Industrials revenue and extended to Molykote.
Innovation mix toward growth
DuPont launched more than 125 new products in 2025 with over $2 billion of new-product sales; the vitality index is in the mid-30% range, and the goal is to move from about 60% replace / 40% growth to 50/50. Gen 4 reverse osmosis from Edina is due in 2027.
AI across innovation, sales and service
Agents in two businesses cut the front-end stage-gate step from about three months to about five days, AI-enabled sales plays lifted Tyvek garments by $5-6 million, and Copilot is available to every exempt employee. Sales pay moves to commission-based from January 1, 2027.

Latest results

In Q3 2026 net sales were $1,868 million, up 4% (organic +5%), and income from continuing operations was $171 million against $102 million a year earlier. Operating EBITDA was $469 million, a 25.1% margin, and cost of sales fell to 64% of sales from 66% on manufacturing productivity. Nine-month sales were $5,368 million (+4%) and operating cash flow from continuing operations was $1,042 million, against $473 million. Full-year 2026 guidance was raised to sales of about $7.19 billion, operating EBITDA of $1.785 billion and adjusted EPS of $7.50 at the midpoint; Q4 is guided at sales of $1.825 billion.

Investments and deals

Healthcare bolt-on acquisitions
DuPont bought Spectrum Plastics (August 2023, about $1,781 million) and Donatelle Plastics (July 2024, $365 million); M&A remains aimed mainly at healthcare, with about $1.5 billion of "firepower" left.
Water capacity in China
Sinochem (Ningbo) RO Memtech, a Chinese reverse osmosis maker, was acquired in October 2025 for $56 million to add RO membrane capacity.
Portfolio separations
Qnity paid DuPont about $4.1 billion at the November 2025 spin, and the Aramids sale closed on April 1, 2026 for about $1.2 billion pre-tax cash, a $300 million note and a $325 million equity interest.
Share buybacks
Under a $2 billion authorization: a $500 million ASR in Q4 2025, a $275 million ASR in Q2 2026, a $250 million ASR in Q3 2026, and a further $250 million planned for Q4 2026.
Capex and restructuring
Capex was $333 million in 2025 with about $320 million expected for 2026. The 2026 DuPont Restructuring Program expects $100-150 million of charges and other cost savings through 2028.

Challenges and risks

PFAS legacy liabilities
The New Jersey settlement (first $71 million payment in September 2026) and the North Carolina settlement of September 9, 2026 add multi-year payments, with Qnity bearing 44% of these funding obligations.
Middle East disruption
The conflict that began in February 2026 disrupts Water sales in the region; about $15 million of large projects with orders in hand were pushed into 2027.
Weak construction and auto markets
About 40% of the portfolio (construction and automotive) is in markets declining low single digits, and Building Technologies volumes fell in 2025 on "ongoing weakness in construction markets".
Separation tax and trade risks
DuPont could owe significant tax if the Qnity, N&B or Dow/Corteva separations fail to qualify as tax-free, and it is exposed to tariffs, export controls and raw-material and energy cost inflation.
Delivery performance gap
On-time-in-full is in the low 80s against a 95% target measured to request date.

What leadership says

“we are not going to make a hasty decision and do a deal just to do a deal.”

Lori Koch, Chief Executive Officer · DuPont Q3 2026 earnings call, November 3, 2026

“While we have the orders in hand for our large water projects in the Middle East, given the continued disruptions, our guidance now assumes these projects will be pushed into 2027”

Lori Koch, Chief Executive Officer · DuPont Q3 2026 earnings call, November 3, 2026

“our portfolio is not a chemical company portfolio”

Antonella Franzen, SVP and Chief Financial Officer · DuPont 4Q 2025 earnings call, February 10, 2026

Where a supplier can help

Productivity and delivery tools
Tied to the business-system priority and the delivery gap: suppliers of lean, maintenance, planning or supply-chain tools could help lift on-time-in-full from the low 80s toward 95% and net productivity toward 3% of COGS.
Commercial excellence and sales enablement
Tied to the AI priority and the move to commission-based sales pay from January 2027: sales-performance, incentive-compensation and AI sales-play tools fit a sales force being re-tooled.
Medical-device contract manufacturing inputs
Tied to healthcare growth and bolt-on M&A: suppliers of components, equipment and quality systems for medical packaging and device manufacturing serve the fastest-growing segment.
Water capacity and semiconductor demand
Tied to water growth and the China RO acquisition: equipment, process and logistics suppliers can support membrane capacity and ion exchange demand from AI data centres.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like DuPont?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about DuPont

What does DuPont do?

DuPont makes engineered materials and solutions for healthcare, water, construction and industrial markets, including Tyvek, FilmTec, Amberlite, Styrofoam, Corian, Vespel and Molykote. It reports two segments: Healthcare & Water Technologies and Diversified Industrials.

What is DuPont's revenue?

Continuing net sales were $6,849 million in 2025, up 2%. For 2026 DuPont guides to sales of about $7.19 billion.

How many employees does DuPont have?

Approximately 15,000 at December 31, 2025, of whom about 1,700 were in the Aramids business that was later sold.

Who leads DuPont?

Lori D. Koch is CEO, Edward D. Breen is Chairman and Antonella B. Franzen is SVP and CFO.

What is DuPont's strategy?

After spinning off Qnity and selling Aramids, DuPont focuses on above-market organic growth in healthcare and water, a business system built on productivity and 80/20, and balanced capital allocation between buybacks and healthcare bolt-on M&A.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)